Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Benitec Biopharma (BNTC) Operating Expenses (2019 - 2025)

Benitec Biopharma has reported Operating Expenses over the past 7 years, most recently at $13.4 million for Q4 2025.

  • Quarterly results put Operating Expenses at $13.4 million for Q4 2025, up 23.8% from a year ago — trailing twelve months through Dec 2025 was $38.2 million (up 45.18% YoY), and the annual figure for FY2025 was $41.8 million, up 85.7%.
  • Operating Expenses reached $13.4 million in Q4 2025 per BNTC's latest filing, up from $9.8 million in the prior quarter.
  • Across five years, Operating Expenses topped out at $13.4 million in Q4 2025 and bottomed at $3.5 million in Q1 2022.
  • Median Operating Expenses over the past 5 years was $5.0 million (2021), compared with a mean of $6.1 million.
  • The largest annual shift saw Operating Expenses soared 77.37% in 2021 before it dropped 7.54% in 2022.
  • Over 5 years, Operating Expenses stood at $4.9 million in 2021, then grew by 15.72% to $5.6 million in 2022, then increased by 23.17% to $6.9 million in 2023, then surged by 55.98% to $10.8 million in 2024, then grew by 23.8% to $13.4 million in 2025.
  • Business Quant data shows Operating Expenses for BNTC at $13.4 million in Q4 2025, $9.8 million in Q3 2025, and $9.8 million in Q2 2025.